The Story

Cellect Biotechnology Ltd. was founded in 2011 by Kasbian Nuriel Chirich, Dr. Shai Yarkoni  with a vision of enabling regenerative medicine to become reality.


Realizing that stem cells are one of the pillars of the 21st century medicine, first development was around enabling the mass enrichment of stem cells as a raw material for any and all regenerative treatments. Without such technologies, stem cells based treatments will remain within the confines of laboratories and clinical trials.


For regenerative medicine to become publicly available for all people, quality stem cells need to become a commodity, easily available in mass for all medicinal purposes.


Cellect was driven by its wish to become the main provider of technologies for pharma companies and medical centers that will make the production of stem cells based products a trivial, safe and inexpensive process.


Based on 15 years of in depth research, Cellect's ApoGraft is the long sought-after methodology that achieves that dream. Backed by 7 families of patents, Cellects’ ApoGraft is aimed at becoming the industry-wide standard for enabling the use of stem cells in a myriad of regenerative medicine treatments.



Dr. Shai Yarkoni

Co-Founder & CEO

Dr. Yarkoni has over 15 Years Of Clinical And Management Experience In The Biopharmaceutical Industry. He Is The Founder Of 5 Start-Ups In The Life-Sciences Field And Serves On The Board Of Noted Institutes In Israel And The World. Prior To Joining Cellect, He Served As CEO Of Target-In Ltd., And As CTO And VP R&D Of Collgard Biopharmaceutical, A Tissue Therapeutics Company. Dr. Yarkoni Has M.D Ph.D From The Hadassah Medical School in Jerusalem, Israel And Is A Board Certified Ob/Gyn. Dr. Yarkoni Is The Author Of Over 60 Scientific Papers.

Nuriel Chirich Kasbian

Co-Founder & Executive  Chairman


An Accomplished Financial / Business Expert Holding Executive Positions In Global Enterprises. Previous Positions held include Founder And General Manager Of Kasbian- LeadCom in Tanzania. Operating In East Africa For The Past 15 Years. Mr. Kasbian Is The Honorary Consul Of Tanzania In Israel.

Eyal Leibovitz



Eyal has over 27 years of experience in senior management, finance, IR, M&A and business development in international pharma and biotech companies. acting as CFO of several NASDAQ/NYSE listed companies including Kamada Ltd. NASDAQ:KMDA and Evogene Ltd. NYSE:EVGN).


Among his many achievements, he led Kamada to a successful large scale funds raising (including PIPE round, public rights offering, venture lending and public convertible debt) and led the sale of N-trig to Microsoft. In all companies he held full responsibility of all financial reporting, budget control, financial planning, strategic negotiations, IR/PR, legal proceedings, operations and HR.


Andrew Sabatier

Chief Business Officer


Andrew has over 20 years of experience in the Biotechnology/Life Sciences market, most recently with GE Cell Therapy, as the Sales and Market Development Leader for the US and Canada.  Prior to GE, from 2010 to 2017, Mr. Sabatier was the VP of Sales of BIOSAFE America, which was acquired by GE. He was responsible for creating the foundation committed to developing the cell processing market, which became the largest market for BIOSAFE, and is currently the cornerstone of GE's cell therapy business. He has managed US commercial operations and built, trained and developed international sales teams across Asia, South America, Europe, Canada, and the United States. Prior to joining BIOSAFE, Mr. Sabatier served in various commercial roles with Gambro, Genzyme, Cook Medical and Toshiba. He is the winner of multiple awards and holds a Bachelor of Arts and International Relations degree from the Boston University, MA.

Dr. Ronit Bakimer-Kleiner

Chief Development Officer


Dr. Bakimer-Kleiner has over twenty years of experience as a scientist and executive manager in the biotechnological industrial environment. She has amassed comprehensive knowledge in cell therapy and GMP manufacturing and has an extensive background in immunology, autoimmunity and cell biology, in management of GMP facilities and tech-transfer. Ronit has been involved in project planning and management, product development from the bench to production. Formerly, Ronit served as the General Manager of Cognate Bioservices LTD. (Israel) and was the laboratory director of the International Center for Cell Therapy & Cancer (ICTC) of Tel Aviv Sourasky Medical Center as well as Director of Cell Therapy at Proneuron Biotechnologies.


Dr. Tamara Byk-Tennenbaum

VP Operations


Tamara Byk-Tennenbaum,Ph.D. MBA, has more than 25 years' experience in the fields of Hematopoietic Stem Cells, hemostasis,  neurobiology and gene therapy. She served as VP Technology Platform at Evogene, R&D Associate Director at Omrix (Ethicon Biosurgery - JnJ) and Scientific Director at Teva. She has extensive management experience in the field of new product development from market research, budgeting, process development and operation to large scale production, marketing and sales. Among her many achievements she established the highly efficient Technology Platform at Evogene and  led the successful launch of SURGIFLO® in  EU and US at Ethicon Biosurgery.


Advisory Board


Susan Alpert, Ph.D., currently the principle of SFA Consulting LLC. Previously, Dr. Alpert joined Medtronic in July 2003 as Vice President of Regulatory Affairs and Compliance.  Prior to joining Medtronic, Susan served  C.R. Bard, Inc., as Vice President of Regulatory Sciences. She also previously worked at the US FDA where she held a variety of management positions in the Centers dealing with drugs, devices and radiological health, and foods. Susan is a microbiologist and paediatrician with a specialty in infectious diseases.

Prof. COREY CUTLER | Harvard Medical School

Corey Cutler, MD, MPH, FRCP(C) is an Associate Professor of Medicine at Harvard Medical School, and a Senior Physician in the Division of Hematologic Oncology, Department of Medical Oncology at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital, Boston, MA.  He is also an Affiliate faculty Member of the Harvard Stem Cell Institute, Cambridge, MA. Currently, Dr. Cutler is on the Board of Directors of the American Society of Blood and Marrow Transplantation and Co-Chair of the Clinical Trials Working Group of the NIH Consensus Conference on Chronic GVHD.

Prof. JOHN F. DiPERSIO | Washington University

Prof. John F. DiPersio, Deputy Director, Alvin J. Siteman Cancer Center and Chief of the Division of Oncology at Washington University School of Medicine in St. Louis and the Virginia E. and Samuel J. Golman Professor of Medicine. Dr. DiPersio is Vice President  of American Society of Blood and Marrow Transplantation, a member of the Board of Scientific Counselors (Clinical Science and Epidemiology) of the National Cancer Institute, an elected member of American Society for Clinical Investigation and American Academy of Physicians (AAP).

Prof. DOV ZIPORI | Weizmann Institute of Science

Prof. Zipori  served for about a decade as the first Director of the Helen and Martin Kimmel Stem Cell Research Institute, at the Weizmann Institute of Science. He was the incumbent of the Joe and Celia Weinstein Professorial Chair. He published over 200 original research articles, reviews, book chapters, and a complete book on stem cell biology. In 2004 he proposed the Stem State theory that foresaw the capacity of mammalian cells to undergo dedifferentiation. Prof. Zipori is currently an adviser at the Department of Molecular Cell Biology, Weizmann Institute of Science.

Prof. Robert S. Negrin | Stanford University


Robert S. Negrin, MD is a Professor of Medicine and Chief of the Division of Blood and Marrow Transplantation at Stanford University. He received his undergraduate degree from the University of California at Berkeley and MD from Harvard University. He trained in medicine and hematology at Stanford University and joined the faculty in 1990.  He has authored over 240 original papers, 42 book chapters and is a co-Editor of Thomas’ Hematopoietic Cell Transplantation.

Board of Directors

Together with Cellect's Chairman and the CEO

Mrs. Ruhama Abraham | Ex Deputy Knesset Speaker

Mrs. Abraham served most of her adult life as a member of the Israeli parliament fulfilling  a wide range of executive government roles  including Minister of Interior Affairs, Knesset Committee Chairwoman, acting member of the Constitution, Law and Justice Committee, Chairwoman of the Lobby for Small and Medium Sized Businesses and Deputy Knesset Speaker. During her career she has amassed an experience in both domestic and foreign affairs and held responsibility of hundreds of billions of  NIS  in budgets. Mrs. Abraham is holding an MBA in Organizational Management and BA in Social Sciences.


Head of Device Business for Medical Devices & Services (MD&S) at Merck. Before joining Merck, David served as Head of Operations and R&D for the Technology and Dymo

Business unit at Newell Brands, a Fortune 500 company, where he led key growth initiatives and large projects, as well as cross-functional teams and manufacturing sites and contractors in Europe, USA and Asia. David also held various system engineering and management roles at Logitech, CERN, and in the medical device, aerospace and consumer electronics industries.


Michael has held top executive positions in Pfizer over a course of 15 years leading the Diabetes unit, Cardiovascular group, Global Medical organization and finally serving as Senior Vice President and Head of Clinical Development and Medical Affairs in the Specialty Care Business Unit. Michael acts as member of the Boards of Directors of Kamada and Recro Pharma and on the Scientific Advisory Boards of DIR Technologies and Verseon Corporation. He has authored and co-authored more than 100 peer-reviewed journal articles and book chapters in his career.


Dr. Ben Yakar Has Over 22 Years Of Experience In The Biomedical Field, Including 15 Years Of Management And Leading Diverse Activities. Dr. Ben Yakar Is The CEO Of BioSight, A Clinical-Phase Biotech Company And A Business Consultant To Biomed Companies. She Formerly Served As CEO Of Biotech Companies Procognia And Thrombotech, As The Chief Business Officer Of YEDA, The Technology Transfer Company Of The Weizmann Institute Of Science, And As VP In Several Biotech Companies.




Yuval Is The Founder And Managing Director Of U.V.B Business Initiatives Ltd., A Business Consultancy Firm Based In Tel Aviv. Previously Yuval Worked In The Investment Banking And Underwriting Units Of A Leading Investment Bank And A Publicly Traded Financial Services Group. Yuval Served As A Board Member Of Several Private Companies As Well As A Publicly Traded Group. He Holds LL.B. And B.A. Degrees In Law And Economics From Tel Aviv University And An MBA From The Solvay Business School, Université Libre De Bruxelles.



Mr. Abraham Nahmias Has Over 30 Years Of Financial Experience Both As A Partner At Nahmias-Grinberg C.P.A. As Well As A Director At 5 Public Companies In Diversified Fields Of Business. Mr. Nahmias Has Earned His B.A In Economics And Accounting From Tel Aviv University Is A Certified Public Accountant By The Accounting Council, Ministry Of Justice, Israel.

Join our mailing list

Submitting Form...

The server encountered an error.

Form received. Thank you.

© 2017 Cellect Biotherapeutics Ltd., all rights reserved  | CODE OF ETHICS